A multicentre, open-label, randomised, phase III trial comparing Velcade [bortezomib]/dexamethasone versus vincristine/Adriamycin (Doxorubicin)/dexamethasone (VAD) for the treatment of patients with multiple myeloma

Trial Profile

A multicentre, open-label, randomised, phase III trial comparing Velcade [bortezomib]/dexamethasone versus vincristine/Adriamycin (Doxorubicin)/dexamethasone (VAD) for the treatment of patients with multiple myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Vincristine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Aug 2013 The European Commission has approved bortezomib induction therapy in combination with dexamethasone or thalidomide + dexamethasone based on the analysis of data from this trial, according to a Janssen-Cilag media release.
    • 28 Jun 2013 Data from this study support a postive opinion from the CHMP of the EMA for bortezomib-based induction regimens, according to a Janssen Cilag media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top